Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Organometallic Compounds
  • Organophosphorus Compounds
  • Prostatic Neoplasms
  • Taxoids

abstract

  • The results of the current study indicate that (153) Sm-EDTMP can be safely combined with docetaxel at full doses on an ongoing basis in patients with mCRPC. Although thrombocytopenia limited therapy for some patients, preliminary efficacy supports the strategy of combining a radiopharmaceutical with chemotherapy, which is an appealing strategy given the anticipated availability of α emitters that can prolong survival.

publication date

  • September 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3775970

Digital Object Identifier (DOI)

  • 10.1002/cncr.28103

PubMed ID

  • 23765638

Additional Document Info

start page

  • 3186

end page

  • 94

volume

  • 119

number

  • 17